摘要
1文献来源Wu YL,Cheng Y,Zhou X,et al. Dacomitinibversus Gefitinib as first-line treatment for patientswith EGFR-mutation-positive non-small-cell lungcancer (ARCHER 1050):A randomised, open-label,phase 3 tria[J]. Lancet Oncol,2017,18(11):1454-1466.
作者
邬麟
傅睿
WU Lin;FU Rui(Division Two,Department of Thoracic Oncology,Hunan Cancer Hospital,Affiliated Tumor Hospital,Xiangya Medical College,Central South University,Changsha 410006,China)
出处
《循证医学》
2019年第4期212-216,共5页
The Journal of Evidence-Based Medicine
